DeCure for Pulmonary alveolar proteinosis with hypogammaglobulinemia
DeCure's autonomous Respiratory AI scientist is researching a drug-repurposing hypothesis for pulmonary alveolar proteinosis with hypogammaglobulinemia — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePulmonary alveolar proteinosis with hypogammaglobulinemia maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for pulmonary alveolar proteinosis with hypogammaglobulinemia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
2'-5'-oligoadenylate synthetase 1 (OAS1) — OAS1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet dtpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4IG8 · 2.7 Å · ligand 2'-DEOXYADENOSINE 5'-TRIPHOSPHATE (DTP). Experimental structure, not a prediction.
What the evidence adds up to
A 2009 case report describes the first use of rituximab in a patient with autoimmune pulmonary alveolar proteinosis, a condition presumed to be autoimmune and unresponsive to steroids, where the standard therapy is whole-lung lavage. The report states only that therapy was successful; it gives no numbers for survival, response rates, or sample size, as it is a single case.
A 2017 case report describes a 30-year-old male sugar cane plantation worker with progressively worsening dyspnoea and non-productive cough for one year, prior recurrent respiratory infections, cyanosis, and bilateral rales. Chest CT showed a diffuse crazy paving pattern. Bronchoalveolar lavage yielded foamy, thick whitish material; cytology showed lymphocytes and acellular proteinaceous eosinophilic material. Transbronchial biopsy confirmed pulmonary alveolar proteinosis. The patient met criteria for whole-lung lavage and responded favourably to that therapy. A 2012 case report notes that three forms of pulmonary alveolar proteinosis are recognised — congenital, secondary, and idiopathic (90% of cases) — and describes a young male patient diagnosed by CT, bronchoscopy, and transbronchial biopsy who was discharged in good health and remained asymptomatic. A 2005 case study provides epidemiology and pathophysiology of the disease and describes a patient treated with whole-lung lavage.
No abstract reports a treatment for pulmonary alveolar proteinosis with hypogammaglobulinemia specifically. The only drug mentioned is rituximab, in a single 2009 case of autoimmune disease, with no controlled data. What is missing is any randomised trial, any evidence linking hypogammaglobulinemia to a specific treatment strategy, and any patient stratification beyond the broad categories of congenital, secondary, and idiopathic.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
European Respiratory Journal · 2009 · 105 citations
Rituximab therapy in autoimmune pulmonary alveolar proteinosis
AbstractIdiopathic pulmonary alveolar proteinosis is presumed to be an autoimmune disorder that may lead to pulmonary insufficiency. However, steroids do not appear to be effective and the standard of therapy is whole-lung lavage. We report the first case of successful therapy with rituximab, which addresses the pathogenic mechanism of pulmonary alveolar proteinosis.
AbstractINTRODUCTION: Pulmonary alveolar proteinosis is a rare, diffuse interstitial lung disease, characterized by alveolar obstruction due to the accumulation of pulmonary surfactant. CLINICAL PRESENTATION: A 30-year-old male with progressively worsening dyspnea and non-productive cough for one year. He was a sugar cane plantation worker and had prior recurrent respiratory infections. Physical exam revealed cyanosis, and bilateral coarse and fine rales. Chest computed tomography showed diffuse crazy paving pattern. Bronchoscopy with bronchoalveolar lavage yielded a foamy, thick whitish material. Cytology revealed lymphocytes and acellular proteinaceous eosinophilic material. Transbronchial biopsy confirmed the diagnosis of pulmonary alveolar proteinosis. Patient met criteria for whole lung lavage, responding favorably to this therapy. CONCLUSION: Pulmonary alveolar proteinosis is a rare lung disease and important to consider due to the diagnostic and therapeutic challenge it represents.
Jornal Brasileiro de Patologia e Medicina Laboratorial · 2012 · 1 citations · open access
Characteristic aspects of alveolar proteinosis diagnosis
AbstractAlveolar proteinosis is an uncommon pulmonary disease characterized by an accumulation of surfactant in terminal airway and alveoli, thereby impairing gas exchange and engendering respiratory insufficiency in some cases. Three clinically and etiologically distinct forms of pulmonary alveolar proteinosis are recognized: congenital, secondary and idiopathic, the latter corresponding to 90% of the cases. In this case report we present a young male patient that was diagnosed with alveolar proteinosis. Computed tomography of the thorax, bronchoscopy and transbronchial biopsy were performed. The histopathologic aspect was characteristic. The patient was discharged in good health conditions and remains asymptomatic to date.
Dimensions of Critical Care Nursing · 2005 · 1 citations
A Case of Pulmonary Alveolar Proteinosis Treated With Whole Lung Lavage
AbstractIn Brief Pulmonary alveolar proteinosis is rarely seen and, thus, many critical care nurses may not be familiar with the disease. This article provides information about the epidemiology, pathophysiology, and a case study of a patient with this disease. The authors present a case study of a patient with pulmonary alveolar proteinosis, a condition that can lead to major respiratory dysfunction. The article includes a brief description of this disorder.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
